Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SenoRx Expands Breast Cancer Business Beyond Biopsies To Disease Therapy

This article was originally published in The Gray Sheet

Executive Summary

SenoRx plans to submit a 510(k) application to FDA in the second half of this year for its Radiation Balloon catheter system for breast cancer treatment

You may also be interested in...



SenoRx breast cancer radiation balloon

Firm will delay until early 2008 a full launch of its multi-lumen Radiation Balloon breast cancer brachytherapy device following 510(k) clearance, announced May 23. SenoRx plans clinical trials to support marketing claims prior to its debut. The minimally invasive device uses a vacuum to remove excess fluid and keep the balloon adhered to irregularly shaped lumpectomy cavities, and its multiple radiation seed lumens enable precise radiation dosing, SenoRx explains. The Aliso Viejo, Calif. company went public in March (1"The Gray Sheet" April 9, 2007, p. 8)...

SenoRx breast cancer radiation balloon

Firm will delay until early 2008 a full launch of its multi-lumen Radiation Balloon breast cancer brachytherapy device following 510(k) clearance, announced May 23. SenoRx plans clinical trials to support marketing claims prior to its debut. The minimally invasive device uses a vacuum to remove excess fluid and keep the balloon adhered to irregularly shaped lumpectomy cavities, and its multiple radiation seed lumens enable precise radiation dosing, SenoRx explains. The Aliso Viejo, Calif. company went public in March (1"The Gray Sheet" April 9, 2007, p. 8)...

Cytyc Pays 10-Times Sales For Proxima, Breast Cancer Therapy Market Entry

Cytyc likely will divest Proxima Therapeutics' GliaSite brain tumor radiation therapy system after acquiring the company for its MammoSite breast cancer system under a $160 mil. deal Feb. 9

Related Content

UsernamePublicRestriction

Register

MT024672

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel